On March 23-25, the first ever conference with focus on FcRn-targeted therapies for autoimmune diseases was held digitally. The 3-day conference brought together key leaders in the field, including academic laboratories and pharmaceutical companies. The focus was on how in-depth knowledge about FcRn biology could be used in development of new treatment options for patients suffering from chronic life-long severe autoimmune diseases.
Jan Terje Andersen had the privilege to give the opening remarks, in addition to give one of the main talks where he discussed FcRn biology in light of innovative biomedical technologies developed in his laboratory.
In this regard, he gave an exclusive interview with the organizers:
Andersen leads the Laboratory of Adaptive Immunity and Homeostasis at the Department of Immunology, Oslo University Hospital, and is a professor at Department of Pharmacology, University of Oslo.